DESTINY-CRC01: trastuzumab deruxtecan in HER2-expressing metastatic colorectal cancer
Trastuzumab deruxtecan shrank tumours in about 45 percent of patients with HER2-high colorectal cancer, including those who had already received other HER2 drugs, but did nothing for tumours with low HER2 expression and carried a risk of lung inflammation.
Overview
Phase 2 study of 86 patients with HER2-expressing, RAS and BRAF wild-type metastatic colorectal cancer after at least two regimens, treated with trastuzumab deruxtecan 6.4 mg/kg in three cohorts by HER2 level.
In the HER2 immunohistochemistry 3+ or 2+ with amplification cohort, objective response was 45.3 percent with median progression-free survival 6.9 months, including responses after prior HER2 therapy; no responses were seen in the low-expression cohorts, and interstitial lung disease occurred in 9 percent with some deaths.
- Objective response 45.3 percent in HER2-positive cohort A; median progression-free survival 6.9 months.
- No responses in HER2 2+ non-amplified or 1+ cohorts; interstitial lung disease 9.3 percent.
Trastuzumab deruxtecan is an option for HER2-positive colorectal cancer after HER2 antibodies, and it contributed to the tumour-agnostic approval for HER2 3+ solid tumours; lung monitoring is essential.
- Single-arm; interstitial lung disease including fatal cases.
- The 6.4 mg/kg dose is higher than that used in breast cancer.
Similar pages
not linked directly; found by shared links- Key paperMOUNTAINEER: tucatinib plus trastuzumab for HER2-positive, RAS wild-type metastatic colorectal cancer
Shares HER2-amplified colorectal cancer, The Lancet Oncology, Trastuzumab.
- Key paperHERACLES: trastuzumab and lapatinib in HER2-amplified, KRAS wild-type metastatic colorectal cancer
Shares HER2-amplified colorectal cancer, The Lancet Oncology, Trastuzumab.
- TrialTL938 and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer
- TrialDESTINY-CRC02
Shares HER2-amplified colorectal cancer, Trastuzumab deruxtecan.
- TrialBeamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People Wit
Shares HER2-amplified colorectal cancer, Trastuzumab deruxtecan, Trastuzumab.
- TrialA Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer
Shares Trastuzumab deruxtecan, Trastuzumab.
- Key paperDESTINY-Lung01: trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer
Shares Trastuzumab deruxtecan, Trastuzumab.
- Key paperDESTINY-Lung02: two doses of trastuzumab deruxtecan in HER2-mutant metastatic non-small-cell lung cancer
Shares Trastuzumab deruxtecan, Trastuzumab.